Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

12.63
+0.07000.56%
Post-market: 12.630.00000.00%16:10 EDT
Volume:64.40K
Turnover:814.41K
Market Cap:2.20B
PE:125.11
High:12.70
Open:12.56
Low:12.55
Close:12.56
52wk High:18.30
52wk Low:9.77
Shares:174.43M
Float Shares:104.00M
Volume Ratio:0.66
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1010
EPS(LYR):2.60
ROE:1.46%
ROA:-1.24%
PB:1.75
PE(LYR):4.86

Loading ...

Hutchmed to Withdraw Cancer Drug in China

MT Newswires Live
·
Mar 09

HUTCHMED Commences Tazverik® Withdrawal and Product Recall

Stock News
·
Mar 09

Hutchmed discontinues all active tazemetostat clinical trials

TIPRANKS
·
Mar 09

CLSA Trims HUTCHMED Target Price to HK$30.40, Keeps Outperform Rating

Stock News
·
Mar 09

Guotai Haitong Sticks to Its Buy Rating for HUTCHMED (China) (HCM)

TIPRANKS
·
Mar 09

HUTCHMED Announces Executive Reshuffle: Dr. Yansi Ya to Assume Senior and Lead Independent Director Role

Stock News
·
Mar 06

Daiwa Capital Markets Adjusts HUTCHMED Target Price to HK$26, Citing Consistent Annual Performance

Stock News
·
Mar 06

Hong Kong Market Announcement Highlights | JD Group Reports 13% Revenue Growth to 1.3091 Trillion Yuan for 2025

Stock News
·
Mar 06

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

GlobeNewswire
·
Mar 05

Hutchmed 2025 Earnings Rise, Revenue Falls

MT Newswires Live
·
Mar 05

HUTCHMED Reports 2025 Financial Results with $457 Million Net Profit Attributable to Shareholders

Stock News
·
Mar 05

Earnings Flash (HCM) Hutchmed Posts 2025 Total Revenue $548.5M, vs. FactSet Est of $563.7M

MT Newswires Live
·
Mar 05

Press Release: HUTCHMED Reports 2025 Full Year Results and Business Updates

Dow Jones
·
Mar 05

Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors

MT Newswires Live
·
Mar 04

HUTCHMED Initiates Global Trial for Novel PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Solid Tumors

Stock News
·
Mar 04

Asure Software Confronts AI Threat to Usage-Based Revenues and HCM Demand

TIPRANKS
·
Feb 28

Press Release: Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Dow Jones
·
Feb 26

Earning Preview: Hutchison China Meditech this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Earnings Agent
·
Feb 26